jcm-logo

Journal Browser

Journal Browser

Cardiovascular Complications in Renal Diseases 2.0

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: closed (25 February 2024) | Viewed by 4201

Special Issue Editors


E-Mail
Guest Editor
1. Head of Department of Interventional Cardiology—Cardiovascular Diseases Institute, 700503 Iasi, Romania
2. Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700115 Iasi, Romania
3. Romanian Academy of Medical Sciences, 030167 Bucharest, Romania
Interests: antithrombotics; dialysis; cardiovascular therapies; anticoagulants; thrombosis; machine learning; artificial intelligence; atrial fibrillation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Nephrology Clinic, Dialysis and Renal Transplant Center, "C.I. Parhon" University Hospital, Iasi, Romania
2. Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, 700115 Iasi, Romania
3. Academy of Romanian Scientists (AOSR), Iasi, Romania
Interests: nephrology; dialysis; atherosclerosis; cardiovascular diseases; blood pressure; endothelial function; arrhythmia
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of a previous Special Issue on “Cardiovascular Complications in Renal Diseases”(https://www.mdpi.com/journal/jcm/special_issues/Cardiovascular_Renal).

It is established that the heart–kidney interrelation is complex, problematic, and leads to multiple pathogenic and clinical consequences and complications that require considerable human and financial resources.

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among patients with end-stage renal disease. The clustering of traditional atherosclerotic and non-traditional risk factors drives the excess rates of coronary and non-coronary CVD in this population. The incidence, severity, and mortality of coronary artery disease, as well as the number of complications arising from its therapy, are higher in dialysis patients than in non-chronic kidney disease patients.

The emergence of new methods of diagnosis and new treatment techniques and molecules has inevitably led to the initiation of many clinical trials to prevent, prematurely detect, or quickly treat any complications (acute or chronic) induced by renal pathology (chronic kidney disease or other renal diseases). Whether it is the early stages of chronic kidney disease or the advanced stages (e.g., G5D, G5T), various aspects of cardiovascular functionality are impacted and require close attention.

This Special Issue aims to review various cardiovascular implications of (acute or chronic) renal diseases and different aspects of diagnosis and various novel/updated therapeutic strategies.

Dr. Alexandru Burlacu
Prof. Dr. Adrian Covic
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal diseases
  • cardiovascular diseases
  • diagnostic strategies
  • guidelines
  • biomarkers
  • artificial intelligence
  • treatment algorithms
  • antithrombotics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1209 KiB  
Article
MCP1 Inverts the Correlation between FGF23 and Omega 6/3 Ratio: Is It Also True in Renal Transplantation?
by Deborah Mattinzoli, Stefano Turolo, Masami Ikehata, Simone Vettoretti, Giovanni Montini, Carlo Agostoni, Costanza Conti, Matteo Benedetti, Piergiorgio Messa, Carlo Maria Alfieri and Giuseppe Castellano
J. Clin. Med. 2023, 12(18), 5928; https://doi.org/10.3390/jcm12185928 - 12 Sep 2023
Viewed by 1062
Abstract
During chronic kidney disease (CKD) progression, an increase in fibroblast growth factor (FGF23) is present. In stage 5, a positive correlation between FGF23 and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) emerges. Hypothesizing that the rising positive correlation between monocyte chemoattractant protein 1 (MCP1) [...] Read more.
During chronic kidney disease (CKD) progression, an increase in fibroblast growth factor (FGF23) is present. In stage 5, a positive correlation between FGF23 and omega-6 (n-6) polyunsaturated fatty acids (PUFAs) emerges. Hypothesizing that the rising positive correlation between monocyte chemoattractant protein 1 (MCP1) and n-6 in stage 4 could be the cause, we previously explored FGF23 and MCP1’s roles in dyslipidemia and cardiovascular risk in CKD. In the present paper, we retraced the study evaluating 40 kidney transplant patients (KTx), a cohort where several factors might modify the previous relationships found. An ELISA and gas chromatography assessed the MCP1, FGF23, and PUFA levels. Despite the FGF23 increase (p < 0.0001), low MCP1 levels were found. A decrease in the n-6/n-3 ratio (p = 0.042 CKD stage 4 vs. 5) lowered by the increase in both n-3 αlinolenic (p = 0.012) and docosapentaenoic acid (p = 0.049) was observed. A negative correlation between FGF23 and the n-6/n-3 ratio in CKD stage 4 (r2 −0.3 p = 0.043) and none with MCP1 appeared. According to our findings, different mechanisms in the relationship between FGF23, PUFAs, and MCP1 in CKD and KTx patients might be present, which is possibly related to the immunosuppressive status of the last. Future research will further clarify our hypothesis. Full article
(This article belongs to the Special Issue Cardiovascular Complications in Renal Diseases 2.0)
Show Figures

Figure 1

Review

Jump to: Research

18 pages, 658 KiB  
Review
Cardiorenal Syndrome: Challenges in Everyday Clinical Practice and Key Points towards a Better Management
by Theodora Georgopoulou, Ioannis Petrakis, Kleio Dermitzaki, Christos Pleros, Eleni Drosataki, Georgios Aletras, Emmanouil Foukarakis, Eirini Lioudaki, Emmanuel Androulakis and Kostas Stylianou
J. Clin. Med. 2023, 12(12), 4121; https://doi.org/10.3390/jcm12124121 - 18 Jun 2023
Cited by 4 | Viewed by 2624
Abstract
Under the term cardiorenal syndrome (CRS) falls an increasing number of patients who present with combined heart and kidney dysfunction. Despite the increasing knowledge concerning CRS pathophysiology, diagnosis, and treatment, many of the aforementioned aspects remain obscure in everyday clinical practice. Some of [...] Read more.
Under the term cardiorenal syndrome (CRS) falls an increasing number of patients who present with combined heart and kidney dysfunction. Despite the increasing knowledge concerning CRS pathophysiology, diagnosis, and treatment, many of the aforementioned aspects remain obscure in everyday clinical practice. Some of the challenges that clinicians face when they treat CRS nowadays is the need for a patient-centered management with early diagnosis, early intervention, the distinction of true kidney injury from permissive renal function deterioration during decongestion therapy, and the development of therapeutic algorithms to guide therapy. Full article
(This article belongs to the Special Issue Cardiovascular Complications in Renal Diseases 2.0)
Show Figures

Figure 1

Back to TopTop